Nuplazid (Pimavanserin): How This Antipsychotic Works for Parkinson's Psychosis and When Telehealth Helps

Last updated: August 26, 2026

Nuplazid (pimavanserin) is an atypical antipsychotic used for hallucinations and delusions that come with Parkinson’s disease psychosis. It is not a first-line medicine for schizophrenia or bipolar mania. It is not a dopamine blocker. That is why movement specialists often prefer it when a typical antipsychotic would worsen tremor or stiffness. This guide covers labeled use, 34 mg once-daily dosing, QT and CYP3A4 cautions, and where a video visit can help versus what still belongs with neurology and in-person cardiac review.

This article is education. It is not a diagnosis and it is not a promise that any clinician will prescribe Nuplazid.

Looking for mental health care online? Klarity Health has 2,000+ licensed providers. Many visits happen by video. Coverage varies by plan. Self-pay is also an option. See online depression treatment options or browse conditions.

TLDR

• Brand: Nuplazid. Generic: pimavanserin (tartrate). DrugBank DB05316. FDA approval April 2016 (Acadia). Not a controlled substance.
• MedlinePlus a616032 (revised November 15, 2023): used for hallucinations and delusions in people with psychosis from Parkinson’s disease. Class: atypical antipsychotic.
• DailyMed NUPLAZID (revised April 2026): indicated for hallucinations and delusions associated with Parkinson’s disease psychosis. Recommended dose: 34 mg by mouth once daily, no titration. With or without food.
• NAMI (last reviewed January 2024): 34 mg capsule and 10 mg tablet. Selective serotonin inverse agonist. Benefit may take up to 2 weeks or longer.
• DailyMed forms: 34 mg capsule (40 mg pimavanserin tartrate = 34 mg free base; NDC 63090-340-30) and 10 mg tablet (11.8 mg tartrate = 10 mg free base; NDC 63090-100-30). Capsules may be opened and sprinkled on 1 tablespoon of applesauce, yogurt, pudding, or a liquid nutritional supplement and eaten at once.
• Boxed warning: older adults with dementia-related psychosis treated with antipsychotics have a higher risk of death. DailyMed cites 17 placebo-controlled trials (about 10 weeks): death risk about 1.6 to 1.7 times placebo; roughly 4.5% vs 2.6%. Nuplazid is not approved for dementia-related psychosis unless the hallucinations and delusions relate to Parkinson’s disease.
• Most common labeled adverse reactions (≥5% and twice placebo): peripheral edema 7% vs 2%; confusional state 6% vs 3%. QT prolongation: avoid known long QT, Class 1A/3 antiarrhythmics, certain antipsychotics and antibiotics. Strong CYP3A4 inhibitors raise exposure (ketoconazole about 1.5× Cmax and 3× AUC); the label says reduce the Nuplazid dose. Strong or moderate CYP3A4 inducers: avoid. Half-life about 57 hours (active metabolite about 200 hours).
• Pivotal 6-week trial (DailyMed section 14): SAPS-PD change −5.79 vs −2.73 on placebo (difference −3.06). Motor scores (UPDRS II+III) did not worsen versus placebo. No D2 affinity of note (Ki >300 nM).
• Telehealth can review history, side effects, and many stable refill questions. New starts in Parkinson’s psychosis usually need a movement or psychiatry clinician who can coordinate with neurology. Chest pain, fainting, severe confusion, or suspected overdose need emergency care. If you are in crisis, call or text 988.

Table of contents

• What Nuplazid is
• How it works
• Approved and related uses
• Nuplazid dosage
• Side effects
• Warnings and who should not take it
• Interactions
• When telehealth is enough
• How a Klarity visit fits
• FAQ

What Nuplazid is

Nuplazid is the U.S. brand for pimavanserin. DailyMed lists it as an atypical antipsychotic. Each 34 mg capsule holds 40 mg of pimavanserin tartrate (34 mg free base). Each 10 mg tablet holds 11.8 mg of the tartrate salt. DEA schedule: none. Packager: Acadia Pharmaceuticals Inc.

DrugBank DB05316 describes it as the first antipsychotic without D2 blocking activity, developed for Parkinson’s disease psychosis. Related Klarity atypical guides: quetiapine (Seroquel), ziprasidone (Geodon), iloperidone (Fanapt), and asenapine (Saphris).

How it works

MedlinePlus says pimavanserin changes the activity of certain natural substances in the brain. DailyMed says the mechanism in Parkinson’s disease psychosis is unclear, but the effect may come from inverse agonist and antagonist activity at serotonin 5-HT2A receptors and, to a lesser extent, 5-HT2C receptors.

DailyMed pharmacodynamics: 5-HT2A Ki 0.087 nM; 5-HT2C Ki 0.44 nM; sigma-1 Ki 120 nM; no appreciable affinity (Ki >300 nM) at 5-HT2B, dopamine (including D2), muscarinic, histaminergic, or adrenergic receptors, or calcium channels. That profile is why the pivotal trial did not show a motor worsening signal versus placebo on UPDRS Parts II+III.

NAMI calls it a selective serotonin inverse agonist and notes that the exact mechanism for Parkinson’s psychosis is unknown. DrugBank likewise stresses the lack of inherent dopaminergic activity, which is the clinical reason clinicians reach for it instead of high-potency D2 blockers such as haloperidol.

Approved and related uses

DailyMed indication: treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. MedlinePlus matches that wording. NAMI lists the same use.

It is not approved for dementia-related psychosis unless those hallucinations and delusions relate to Parkinson’s disease. DrugBank notes a later dementia-related psychosis program that did not receive FDA approval as of April 2021. DailyMed also states that safety and effectiveness for irritability associated with autism spectrum disorder have not been established (pediatric study NCT05523895 did not demonstrate effectiveness).

Off-label requests for schizophrenia, bipolar mania, or insomnia are not a reason to expect this drug from an online visit. Your clinician matches the indication to your history.

Nuplazid dosage

Always follow the dose on your prescription. DailyMed recommended dose: 34 mg orally once daily, without titration. Take with or without food. A high-fat meal did not meaningfully change Cmax or AUC.

NAMI: recommended dose 34 mg once daily; you may need a lower dose if you take certain medicines. MedlinePlus: usually once daily; swallow capsules whole, or open and sprinkle the contents on one tablespoon of applesauce, yogurt, pudding, or a liquid nutritional supplement and consume immediately without chewing.

The 10 mg tablet exists so a clinician can adjust the dose when a strong CYP3A4 inhibitor is on board. DailyMed: ketoconazole raised Cmax about 1.5-fold and AUC about 3-fold; population modeling found 10 mg with ketoconazole similar to 34 mg alone. Strong or moderate CYP3A4 inducers (for example rifampin: Cmax down 71%, AUC down 91%) should be avoided because they strip exposure.

No dose change is required for age, sex, ethnicity, or weight. DailyMed: no adjustment for mild to severe renal impairment or ESRD, but use caution in severe renal impairment and ESRD because exposure rose in a renal study. No adjustment recommended for hepatic impairment based on the dedicated study. Pediatric use is not established.

Missed dose (MedlinePlus and NAMI): take it when you remember unless it is almost time for the next dose. Do not double.

Half-life is long: about 57 hours for pimavanserin and about 200 hours for the active N-desmethyl metabolite AC-279. Median Tmax is about 6 hours (range 4-24). Plasma protein binding is about 95%. Apparent volume of distribution after 34 mg is about 2173 L.

Side effects

DailyMed most common reactions (≥5% and twice placebo) in 6-week PDP trials: peripheral edema 7% vs 2%; confusional state 6% vs 3%. Other events ≥2% and greater than placebo included nausea 7% vs 4%, constipation 4% vs 3%, hallucination 5% vs 3%, and gait disturbance 2% vs <1%.

Discontinuations: 8% on 34 mg vs 4% on placebo. Events in more than one patient and at least twice placebo: hallucination, urinary tract infection, and fatigue.

MedlinePlus common effects: nausea, constipation, swelling of hands, ankles, or feet, sleepiness. Get urgent care for new or worse hallucinations, confusion, trouble walking, rash, hives, swelling of the face or tongue, throat tightness, or shortness of breath.

Postmarketing (DailyMed): rash, urticaria, angioedema-type reactions, somnolence, falls, agitation, aggression, fecal incontinence.

NAMI also flags dizziness, falls, orthostatic blood-pressure drops, and the class risk of sudden cardiac death from arrhythmia. Use the smallest effective dose when benefits outweigh risks. Your clinician may order an ECG.

Warnings and who should not take it

Boxed warning. Antipsychotics raise all-cause death risk in older adults with dementia-related psychosis. DailyMed: 17 trials, about 10 weeks, risk 1.6-1.7× placebo; death rates about 4.5% vs 2.6%. Most deaths looked cardiovascular or infectious. Nuplazid is not approved for dementia psychosis unless the symptoms are Parkinson’s-related.

QT prolongation. DailyMed: avoid known QT prolongation and other QT-prolonging drugs (Class 1A: quinidine, procainamide; Class 3: amiodarone, sotalol; certain antipsychotics such as ziprasidone, chlorpromazine, thioridazine; certain antibiotics such as gatifloxacin, moxifloxacin). Also avoid a history of cardiac arrhythmias, symptomatic bradycardia, low potassium or magnesium, and congenital long QT. Thorough QT study: maximum mean change 13.5 msec (upper 90% CI 16.6) at twice the therapeutic dose. In 6-week trials, mean QTc rose about 5-8 msec on 34 mg.

Contraindication. Known hypersensitivity to pimavanserin or any component. DailyMed lists rash, urticaria, and angioedema-type reactions.

Pregnancy and lactation. DailyMed: no human data that allow a risk estimate. Animal studies were not teratogenic at high multiples of the human dose; maternal toxicity and lower pup survival occurred in rats at about 2× the 34 mg MRHD. U.S. background risk of major birth defects is 2-4% and miscarriage 15-20% in recognized pregnancies. No data on human milk. NAMI advises caution if breastfeeding.

If you are in crisis, call or text 988. Overdose: poison control 1-800-222-1222. DailyMed: start cardiac monitoring including continuous ECG; do not use disopyramide, procainamide, or quinidine as antiarrhythmics because they add QT risk. There is no specific antidote.

Interactions

Tell every clinician and pharmacist about prescriptions, OTC products, and herbals. MedlinePlus specifically flags St. John’s wort.

DailyMed clinically important groups:

• Other QT-prolonging drugs: avoid combinations that stack QT risk.
• Strong CYP3A4 inhibitors (examples NAMI lists: itraconazole, ketoconazole, clarithromycin, indinavir): reduce the Nuplazid dose.
• Strong or moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): avoid.

DailyMed: no dosage adjustment of carbidopa/levodopa is required with Nuplazid. Pimavanserin did not meaningfully change midazolam pharmacokinetics.

When telehealth is enough

A licensed telehealth clinician can take a history, review current Parkinson’s medicines, screen for QT risk and interacting drugs, and discuss whether hallucinations or delusions need a medicine change. Many Medicare telehealth flexibilities run through December 31, 2027 after the February 5, 2026 policy extension (HHS telehealth policy updates). Coverage still varies by plan.

Parkinson’s disease psychosis is usually managed with a neurologist or movement-disorder team. A video psychiatrist can collaborate, but a new Nuplazid start often needs that specialty context, a recent medication list, and sometimes an ECG. Depot shots and emergency motor crises are not video-only problems.

Go to emergency care for chest pain, fainting, a very fast or irregular heartbeat, severe confusion, swelling of the face or tongue, or suspected overdose.

How a Klarity visit fits

Klarity Health offers online visits with 2,000+ licensed providers for many mental health and primary-care questions. A visit can cover mood symptoms, medication side effects, and whether a referral or in-person workup is safer. Insurance may help pay for care. Benefits vary by plan. Verify coverage before you book. Self-pay is also available.

See online depression and mood treatment options or browse condition pages.

Klarity clinicians do not promise any specific medicine, including Nuplazid. Prescribing depends on your history, state rules, and clinical judgment.

FAQ

Is there a generic for Nuplazid?

The chemical name is pimavanserin. Brand product on U.S. labels is Nuplazid from Acadia. Whether a pharmacy substitutes a generic depends on what is on the market and on your plan. Ask the pharmacist what they will dispense.

Does Nuplazid treat schizophrenia?

The FDA-labeled use is Parkinson’s disease psychosis. It is not a substitute for standard schizophrenia antipsychotics. A clinician decides any other use.

Will it worsen Parkinson’s motor symptoms?

DailyMed reports no worsening versus placebo on UPDRS Parts II+III in the pivotal trial. That matches the lack of D2 blockade. Individual responses still vary. Report new stiffness or falls promptly.

How long until it works?

NAMI: significant change may take up to 2 weeks; some people need longer, even a couple of months, for the full effect. DailyMed’s primary endpoint was week 6 on SAPS-PD.

Can I take it with carbidopa/levodopa?

DailyMed says no carbidopa/levodopa dose adjustment is required based on interaction studies. Still tell your neurologist about every change.

Is Nuplazid a controlled substance?

No. DailyMed lists DEA schedule as none.

Sources

• DailyMed NUPLAZID (pimavanserin) prescribing information
• MedlinePlus: Pimavanserin
• NAMI: Pimavanserin (Nuplazid)
• DrugBank DB05316: Pimavanserin
• HHS telehealth policy updates

Educational content only. Not medical advice. Coverage and prescribing decisions vary. If you are in crisis, call or text 988.